BBK was engaged to support enrollment in South Korea for a study of a PD-1 immune checkpoint inhibitor in patients with esophageal cancer refractory or intolerant to common treatment.
To generate awareness, BBK developed a program that directed physicians to alert their eligible patients about the study and encourage them to contact principal investigators directly.
Leveraging BBK’s network of Korean physicians who specialize in esophageal cancer, BBK identified, evaluated and reached out to 105 physicians with direct-to-physician emails. Additionally, we conducted 157 phone calls with Korean physicians and site staff to raise awareness for the study and to encourage referrals.
In just six weeks, the physician website had 47 unique visitors. 27 physicians expressed interest in referring 1 or more of their patients to the study, exceeding expectations.
Download the PDF version of this case study today: